EPISODE · Sep 2, 2019 · 9 MIN
ESC Congress 2019 - Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial
from ESC Cardio Talk · host European Society of Cardiology
With Roxana Mehran, The Mount Sinai Hospital - USA, Jan Steffel, University Hospital Zurich - Switzerland & Diana Gorog, University of Hertfordshire - UK Link to paper:
Embed this episode
Ready to play
ESC Congress 2019 - Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial
0:00
9:47
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of ESC Cardio Talk?
This episode is 9 minutes long.
When was this ESC Cardio Talk episode published?
This episode was published on September 2, 2019.
Can I download this ESC Cardio Talk episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!